Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

@article{Sandor2002PhaseIT,
  title={Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.},
  author={Victor Sandor and Susan Bakke and Robert W. Robey and Min Ho Kang and Mikhail V. Blagosklonny and Jonathon Bender and Rebecca Brooks and Richard L. Piekarz and Eben Tucker and William D. Figg and Kenneth K Y Chan and Barry R. Goldspiel and Antonio Tito Fojo and Stanley P. Balcerzak and Susan E Bates},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2002},
  volume={8 3},
  pages={718-28}
}
PURPOSE The primary objectives of this trial were to define the maximum tolerated dose (MTD) and to characterize the toxicities and pharmacokinetics of depsipeptide (FR901228) given on a day-1 and day-5 schedule every 21 days. A secondary objective of the trial was to seek evidence of antineoplastic activity. PATIENTS AND METHODS Patients with advanced or refractory neoplasms received depsipeptide by a 4-h i.v. infusion on days 1 and 5 of a 21-day cycle. On the basis of preclinical data… CONTINUE READING